Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytosorbents Corp (CTSO)
NASDAQ:CTSO
Holding CTSO?
Track your performance easily
CTSO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.70 - $2.15
Previous Close$1.42
Volume71.87K
Average Volume (3M)108.09K
Market Cap
$76.20M
Enterprise Value$95.60M
Total Cash (Recent Filing)$8.46M
Total Debt (Recent Filing)$26.77M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Nov 06, 2024EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding54,306,415
10 Day Avg. Volume126,524
30 Day Avg. Volume108,092
Standard Deviation0.22
R-Squared0.01
Alpha-0.00845
Financial Highlights & Ratios
Price to Book (P/B)4.58
Price to Sales (P/S)2.18
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.67
Enterprise Value/Gross Profit5.58
Enterprise Value/Ebitda-3.56
Forecast
1Y Price Target
$5.50Price Target Upside292.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cytosorbents News
PremiumCompany Announcements
CytoSorbents Announces CFO Transition and New Financial Leadership
PremiumCompany Announcements
CytoSorbents Regains Compliance, Continues on NasdaqBulls Say, Bears Say
Bulls Say
Clinical SuccessA post-hoc analysis showed that the use of DrugSorb-ATR resulted in a significant reduction in severe bleeding complications in patients who underwent coronary artery bypass graft surgery.
Market RecoveryThe quarter saw significant recovery in the Central European markets especially as post-COVID headwinds dissipate.
New Product LaunchThe company plans to launch PuriFi, a novel hemoperfusion pump, in select international markets where hemodialysis infrastructure is lacking.
Bears Say
Clinical StudyThe study did not meet its primary endpoint of reduction in the incidence of clinically significant peri-operative bleeding events.
Financial PerformanceManagement announced that the company is looking at cost-cutting measures and is actively seeking new debt financing to extend the cash runway.
Regulatory ApprovalAgencies may require a confirmatory study before granting approval based on the significant results from post-hoc analyses.
---
Ownership Overview
50.10% Insiders
7.65% Mutual Funds
23.56% Other Institutional Investors
18.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CTSO FAQ
What was Cytosorbents Corp’s price range in the past 12 months?
Cytosorbents Corp lowest stock price was $0.70 and its highest was $2.15 in the past 12 months.
What is Cytosorbents Corp’s market cap?
Currently, no data Available
When is Cytosorbents Corp’s upcoming earnings report date?
Cytosorbents Corp’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Cytosorbents Corp’s earnings last quarter?
Cytosorbents Corp released its earnings results on Aug 13, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.098 by $0.018.
Is Cytosorbents Corp overvalued?
According to Wall Street analysts Cytosorbents Corp’s price is currently Undervalued.
Does Cytosorbents Corp pay dividends?
Cytosorbents Corp does not currently pay dividends.
What is Cytosorbents Corp’s EPS estimate?
Cytosorbents Corp’s EPS estimate is -$0.07.
How many shares outstanding does Cytosorbents Corp have?
Cytosorbents Corp has 54,429,620 shares outstanding.
What happened to Cytosorbents Corp’s price movement after its last earnings report?
Cytosorbents Corp reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.098. Following the earnings report the stock price went up 7.778%.
Which hedge fund is a major shareholder of Cytosorbents Corp?
Among the largest hedge funds holding Cytosorbents Corp’s share is Royce & Associates LLC. It holds Cytosorbents Corp’s shares valued at N/A.
---
Cytosorbents Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (292.86% Upside)
$5.50 (292.86% Upside)
Hedge Fund Trend
Decreased
By 349.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.28%
12-Months-Change
Fundamentals
Return on Equity
-125.05%
Trailing 12-Months
Asset Growth
1.87%
Trailing 12-Months
Company Description
Cytosorbents Corp
CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
---
CTSO Earnings Call
Q2 2024
0:00 / 0:00
---
CTSO Stock 12 Month Forecast
Average Price Target
$5.50
▲(292.86% Upside)
Technical Analysis
Best Analysts Covering CTSO
1 Year
1 Year Success Rate
13/27 ratings generated profit
1 Year Average Return
+6.25%
initiated a buy rating 2 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 48.15% of your transactions generating a profit, with an average return of +6.25% per trade.
---